FTRE (Fortrea Holdings) Quality Rank


FTRE Fortrea Holdings Inc FTRE
64 GF Score
Price $17.77
GF Value $18.22
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Fortrea Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Fortrea Holdings Quality Rank Related Terms

FTRE
64GF Score
Fortrea Holdings Inc FTRE
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fortrea Holdings (FTRE) Overvalued in 2026?

Based on GuruFocus' analysis, Fortrea Holdings stock appears to be undervalued. The current stock price of $17.77 is trading 2.5% below its estimated GF Value™ of $18.22. GuruFocus considers Fortrea Holdings to be Fairly Valued.

Key valuation signals for FTRE:

  • Quality Rank:
  • GF Value™: $18.22 vs. price of $17.77 (2.5% below fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the FTRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortrea Holdings Business Description

Other Exchanges K67:Germany
Address 8 Moore Drive, Durham, NC, USA, 27713
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
64GF Score

Get the complete analysis for FTRE

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.77
Price
$18.22
GF Value